



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostics.com

Date: October 13, 2025

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Approval of Board regarding ₹104.13 Cr Fund raise via Pref Issue and Strategic Partnership with Jeena Sikho Lifecare Limited

Trading Symbol: CHANDAN
ISIN: INE0B2N01016

Dear Sir/Madam,

In Compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are pleased to submit a press release, titled “**Chandan Healthcare Limited Board Approves ₹104.13 Cr Fund Raise Via Pref Issue; Forges Strategic Partnership with Jeena Sikho Lifecare Limited**” issued by the Company, the content of which is self-explanatory.

This is for the information of the exchange and the members.

You are requested to take the same on record.

Yours sincerely,
For Chandan Healthcare Limited

Rajeev Kumar Nain
Company Secretary & Compliance Officer



Chandan Healthcare Limited Board Approves ₹104.13 Cr Fund Raise Via Pref Issue; Forges Strategic Partnership with Jeena Sikho Lifecare Limited

Lucknow, India – October 11th, 2025 Chandan Healthcare Limited (NSE - CHANDAN), – Chandan Healthcare Limited, one of the leading players in North India's diagnostics and healthcare services sector, announced two significant developments that mark a new phase of strategic growth, approval of a ₹104.13 Cr fund raises through a preferential issue of warrants and an exclusive nationwide diagnostic partnership with Jeena Sikho Lifecare Limited.

The Board of Directors of Chandan Healthcare Limited has approved the issuance of **up to 44,50,000 fully convertible equity warrants** on a **preferential basis** at an issue price of ₹ 234 per warrant, aggregating to approximately **₹ 104.13 Cr**, subject to shareholder and regulatory approvals.

Each warrant will be convertible into one fully paid-up equity share of face value ₹10. The issue has been structured to include both **promoter group participation** and **strategic institutional investors**, underscoring strong market confidence in the company's future growth trajectory.

Allotment Summary

- **Promoter & Promoter Group:** 4,75,000 warrants (including Mr. Amar Singh – Promoter & Managing Director, Mrs. Asmita Singh – Promoter & Managing Director, and other Promoter Group members)
- **Non-Promoter Group:** 39,75,000 warrants (including Jeena Sikho Lifecare Limited – 18,00,000 warrants, NEGEN Undiscovered Value Fund, NEGEN Capital Services Private Limited, and other institutional and individual investors)

Chandan Healthcare has also entered into an **exclusive strategic partnership** with **Jeena Sikho Lifecare Limited**, one of India's leading Ayurvedic healthcare providers, to establish **diagnostic centres across all existing and upcoming Jeena Sikho hospitals and clinics across India**.

Key Highlights of the Collaboration:

- **Exclusive Partnership:** Chandan will act as the exclusive diagnostic partner for all Jeena Sikho hospitals and clinics across 23 states and 100+ cities.
- **Comprehensive Services:** The company will provide **end-to-end pathology and radiology solutions** for both IPD and OPD patients.
- **Enhanced Accessibility:** The initiative aims to expand access to **high-quality, affordable, and tech-enabled diagnostic services** across India, aligning with both organizations shared vision of holistic healthcare delivery.

This collaboration significantly expands Chandan Healthcare's national footprint, strengthening its position as a leading integrated healthcare provider with presence across diagnostics, hospitals, and retail pharmacy.

Commenting on the development, Mr. Amar Singh, Promoter and Managing Director of Chandan Healthcare Limited, said, "Both the fund raise and the strategic partnership with Jeena Sikho mark pivotal steps in Chandan's journey toward becoming one of India's most trusted integrated healthcare brands. The strong response from investors reflects deep confidence in our business model and growth strategy.

A major part of the funds raised will be deployed towards **organic and inorganic expansion**, including setting up **new diagnostic laboratories**, upgrading infrastructure, and strengthening **working capital** to support our fast-growing operations. This infusion will enable us to enhance capacity, deepen market presence, and accelerate our pan-India growth momentum.

The collaboration with Jeena Sikho Lifecare Limited represents a strong synergy between Chandan's advanced diagnostic expertise and Jeena Sikho's deep-rooted presence in Ayurvedic healthcare. Together, we aim to bridge the gap between modern medicine and traditional wellness, creating a holistic model of patient care.

This partnership will significantly expand our national footprint, enabling us to bring world-class, technology-driven diagnostic services to more regions across India, and make high-quality, affordable healthcare accessible to every individual."

About Jeena Sikho Lifecare Limited

Jeena Sikho Lifecare Limited (JSLL) is one of India's leading Ayurvedic healthcare providers with over a decade of experience in holistic wellness. The company operates a nationwide network of 55 hospitals and 74 clinics/daycare centres across 21 states and 100+ cities, offering more than 1,500 operational beds with additional capacity in the pipeline.

JSLL follows a hub-and-spoke model, where its clinics drive patient volumes to nearby hospitals, enhancing accessibility and operating efficiency. Alongside its clinical network, the company also retails Ayurvedic health products under the "Shuddhi" brand, supported by a robust pan-India distribution system, digital platforms, and proactive call-centre operations.

By integrating traditional Ayurvedic principles with modern healthcare practices, Jeena Sikho Lifecare Limited continues to advance its mission of delivering affordable, accessible, and holistic healthcare across India.

About Chandan Healthcare Limited

Chandan HealthCare Limited, established in 2003, is a leading North India-based diagnostics company and a part of the Chandan Group. The company has a strong presence across Uttar Pradesh, Uttarakhand, Rajasthan, and Bihar, with expansion plans in Madhya Pradesh, Delhi, and Chhattisgarh. It offers comprehensive pathology, radiology, and diagnostic services under one roof, operating 40 diagnostic centres and over 360 collection centres. Chandan's customer-centric, company-owned model builds trust and ensures quality. Its pharmacy division, Chandan Pharmacy Limited, complements its integrated healthcare offerings.

Key Strengths & Achievements

- **One-Stop Diagnostics:** Delivers over 1,400 pathology and radiology tests through 10 NABL-accredited labs and 5 NABH MIS-accredited centres, supported by 1,300 skilled professionals.
- **Consistent Quality:** Ensures high standards via a company-operated model, backed by experienced leadership and a loyal workforce.
- **Diversified Revenue Streams:** Serves B2C and B2B markets, including individual diagnostics, hospital partnerships, and government contracts, alongside a growing pharmacy division.
- **Cost-Efficient Operations:** Uses refurbished high-end machines to optimise costs while maintaining test accuracy.
- **Customer Loyalty:** Drives repeat business through localised pricing, personalised care, and a strong presence in underserved Tier 2/3 markets.
- **Robust Financials:** In FY25, achieved ₹230.12 Cr in revenue, ₹43.38 Cr in EBITDA, and ₹22.17 Cr in profit, reflecting strong growth and operational efficiency.

Scale & Growth Trajectory

- **Expanding Footprint:** Operates across Uttar Pradesh, Uttarakhand, Rajasthan, and Bihar, with upcoming centres in Madhya Pradesh, Delhi, and Chhattisgarh.

- **Chandan Medical Centres (CMCs):** Innovative local hubs offering collection, pharmacy, and teleconsultation services to penetrate new markets.
- **Strategic Growth:** Expanding in Western UP through selective franchising for pathology services, while enhancing digital platforms and direct-to-consumer channels to drive scalable growth.

Chandan HealthCare is a trusted leader in diagnostics, blending a strong presence in North India with disciplined expansion and customer-focused innovation. With robust financials and a clear growth strategy, it is well-positioned to deliver value to investors and transform healthcare across emerging and metro markets.

The company was listed on NSE Emerge on 17th February 2025.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.